What are the appropriate indications, dosing regimen (including renal adjustments), contraindications, drug interactions, and monitoring recommendations for fenofibrate in adult patients?

Fenofibrate: Clinical Guide

Fenofibrate is indicated as adjunctive therapy to diet for primary hypercholesterolemia/mixed dyslipidemia and severe hypertriglyceridemia (≥500 mg/dL), but it has NOT been shown to reduce cardiovascular mortality in type 2 diabetes and should only be combined with statins when triglyceride-lowering benefits clearly outweigh risks. 1

Indications

Fenofibrate is FDA-approved for:

• Primary hypercholesterolemia or mixed dyslipidemia: To reduce LDL-C, total cholesterol, triglycerides, and apolipoprotein B, while increasing HDL-C 1
• Severe hypertriglyceridemia: Triglycerides ≥500 mg/dL (≥5.65 mmol/L) 1

Critical Limitation

Fenofibrate was NOT shown to reduce coronary heart disease morbidity or mortality in patients with type 2 diabetes mellitus 1. The ACCORD-Lipid trial demonstrated that fenofibrate added to simvastatin did not reduce cardiovascular events overall, though a subgroup with triglycerides ≥204 mg/dL and HDL-C ≤34 mg/dL may have benefited 2.

Dosing Regimen

Standard Dosing

• Primary hypercholesterolemia/mixed dyslipidemia: 160 mg once daily with meals 1
• Severe hypertriglyceridemia: 54-160 mg once daily with meals (maximum 160 mg) 1

Must be taken with food to optimize absorption 1.

Renal Dose Adjustments

This is critical and non-negotiable:

• eGFR ≥60 mL/min/1.73 m²: Standard dosing
• eGFR 30-59 mL/min/1.73 m²: Maximum dose 54 mg daily 2, 1
• eGFR <30 mL/min/1.73 m²: CONTRAINDICATED - do not use 2, 1
• Dialysis patients: CONTRAINDICATED 1

Geriatric Patients

Select dose based on renal function using the adjustments above 1. Elderly patients are at higher risk for fenofibrate-associated creatinine increases 3.

Contraindications

Absolute contraindications 1:

• Severe renal dysfunction (eGFR <30 mL/min/1.73 m²) or dialysis
• Active liver disease
• Gallbladder disease
• Known hypersensitivity to fenofibrate
• Nursing mothers

Drug Interactions

High-Risk Interactions

1. Gemfibrozil + Statin

• Never combine gemfibrozil with statins due to significantly increased risk of rhabdomyolysis 2

2. Fenofibrate + Statin

• May be considered with low- or moderate-intensity statins ONLY if benefits for ASCVD risk reduction or triglyceride lowering (when TG ≥500 mg/dL) outweigh risks 2
• Risk of myopathy/rhabdomyolysis is increased, particularly in elderly, diabetic, renally impaired, or hypothyroid patients 1
• Fenofibrate is safer than gemfibrozil when combined with statins 2

3. Warfarin/Coumarin Anticoagulants

• Fenofibrate potentiates anticoagulant effects 1, 4
• Monitor INR at least 3 times weekly when initiating fenofibrate 4
• Adjust warfarin dose to maintain target INR and prevent bleeding 1
• Effect occurs within 5-10 days 4

4. Medications Affecting Renal Hemodynamics

• ACE inhibitors and ARBs may predispose to fenofibrate-associated creatinine increases 3
• Use caution and monitor renal function closely

5. Bile Acid Resins

• Separate administration; take fenofibrate at least 1 hour before or 4-6 hours after bile acid resins 1

Monitoring Requirements

Renal Function Monitoring (Mandatory)

Assess both serum creatinine AND eGFR 2:

• Baseline: Before initiation
• 3 months: After initiation
• Every 6 months: Ongoing during therapy

Action thresholds:

• If eGFR persistently decreases to <30 mL/min/1.73 m², discontinue fenofibrate immediately 2
• Creatinine increases are typically rapid (within weeks), often reversible, and may not represent true nephrotoxicity 3
• Increases ≥30% warrant consideration of discontinuation 3

Hepatic Monitoring

Monitor liver function including ALT, AST, and total bilirubin 1:

• Baseline: Before initiation
• Periodically: Throughout therapy duration
• Discontinue if: Signs/symptoms of liver injury develop or elevated enzymes persist (>3× ULN) 1

Serious drug-induced liver injury, including liver transplantation and death, has been reported 1.

Lipid Panel Monitoring

• Obtain fasting lipid panel at 4-12 weeks after initiation or dose adjustment 2
• Then every 3-12 months thereafter 2

Muscle Toxicity Monitoring

• Monitor for myalgia, muscle weakness, or dark urine
• Check CK if symptoms develop
• Note: Classic triad of myalgia, weakness, and dark urine is often absent in fenofibrate-associated rhabdomyolysis 5
• In older patients with CKD, unexplained renal deterioration or nonspecific symptoms (nausea, poor appetite) should prompt CK and myoglobin measurement 5

Other Monitoring

• Gallbladder: If cholelithiasis suspected, obtain gallbladder studies 1
• Complete blood count: As clinically indicated

Common Pitfalls and Caveats

Renal Function Misinterpretation

• Fenofibrate causes reversible increases in serum creatinine that may not reflect true renal injury 3
• The mechanism likely involves reduced renal plasma flow and glomerular pressure, not nephrotoxicity 3
• Long-term studies show fenofibrate may actually slow progression of albuminuria and nephropathy 2, 3
• Do not panic with modest creatinine increases, but monitor closely and discontinue if eGFR falls below 30 2

Cardiovascular Benefit Uncertainty

• Do not prescribe fenofibrate expecting mortality benefit in diabetic patients 1
• Evidence suggests benefit primarily in patients with high triglycerides (≥204 mg/dL) AND low HDL-C (≤34 mg/dL) 2
• Women with well-controlled diabetes had higher CVD event rates with fenofibrate-simvastatin versus simvastatin alone 2

Atypical Rhabdomyolysis Presentation

• In elderly patients with CKD, rhabdomyolysis may present with only nonspecific GI symptoms without classic myalgia 5
• Maintain high index of suspicion in at-risk populations

Polypharmacy Risk

• Older patients with CKD on multiple medications (especially ACE-I/ARBs, statins) are at highest risk for adverse effects 3, 5
• Calculate eGFR before prescribing - do not rely on serum creatinine alone 5

Adverse Effects

Most common (>2% and >1% greater than placebo) 1:

• Abnormal liver tests
• Increased AST/ALT
• Increased CPK
• Rhinitis

Serious adverse effects 1:

• Hepatotoxicity (including liver transplantation and death)
• Myopathy and rhabdomyolysis
• Pancreatitis
• Pulmonary embolism
• Acute hypersensitivity reactions (anaphylaxis, angioedema)
• Severe cutaneous adverse drug reactions

Metabolic effects 2:

• Increased creatinine (average 0.113-0.136 mg/dL)
• Cholelithiasis risk